Skip to main content
. 2023 Feb 26;5(5):100716. doi: 10.1016/j.jhepr.2023.100716

Fig. 2.

Fig. 2

Plasma IHH is increased in patients with NASH and NASH-associated liver fibrosis.

(A) Plasma IHH concentrations in control participants (n = 29), participants with steatosis (n = 17), and participants with NASH + fibrosis (n = 50) from cohort 1. (B and C) Data from (A) were stratified based on NAS and fibrosis score. (D and E) Pearson R correlation of the relationship between plasma IHH (LogIHH) and serum ALT (LogALT) or AST (LogAST) in cohort 1. (F and G) Serum IHH in participants without NAFLD (control; n = 4) or with NASH (n = 18) and Pearson R correlation of the relationship between serum and liver IHH in participants from cohort 2. (H) Serum IHH in obese participants with NASH without or with fibrosis (n = 22 and 25, respectively) from cohort 3. Grouped data were analysed using one-way ANOVA. For (A)–(C), (F), and (H), the data are expressed as mean ± SE relative to the first group in each graph (∗p <0.05, ∗∗p <0.01, ∗∗∗p <0.001). ALT, alanine aminotransferase; AST, aspartate aminotransferase; IHH, Indian hedgehog; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis.